Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
Related research Other compounds studied in the same research area
Standards of Care in Diabetes, 2024
CJC-1295 (NO DAC) + Ipamorelin Blend Peptide Research Applications & Key Findings Growth Hormone Secretion Research Pituitary Function Studies Extensive research has examined the growth hormone secretagogue properties of the CJC-1295 + Ipamorelin combination across multiple species: Dose-dependent GH release demonstrated in rat anterior pituitary cell cultures with picomolar to micromolar peptide concentrations 2- to 10-fold increases in plasma growth hormone levels sustained for 6 days in human subjects following single CJC-1295 dose Preserved pulsatile secretion with ipamorelin addition, preventing continuous non-physiological stimulation Selective action on growth hormone release without affecting prolactin, ACTH, cortisol, FSH, or TSH levels Human trials with healthy subjects aged 21-61 years demonstrated sustained, dose-dependent increases in growth hormone and IGF-1 levels that were safe and well-tolerated at doses of 30-60 mcg/kg
This is due to poor oral glutathione absorption in the gastrointestinal tract
Da kommt man in den Knast, wenn man als nicht-Arzt bei Osteoporose sagt, dass man Mehr als 4000 I.E
US$ 23.22
US$ 22.21
US$ 29.84
US$ 24.38
US$ 21.16